Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 1.00 |
| ▸ | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | P62805 | 2/20 | 0.63 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16491979 | 0.90 | BRD4 (0.86) | BRD4H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | |
| SCHEMBL16491980 | 0.89 | BRD4 (1.00) | BRD4H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16PDE3BPDE3A | |
| SCHEMBL16512065 | 0.87 | BRD4 (0.81) | BRD4H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16PDE3BPDE3A | |
| SCHEMBL16486421 | 0.86 | BRD4 (0.80) | BRD4H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16PDE3BPDE3A | |
| SCHEMBL7312860 | 0.85 | BRD4 (0.74) | BRD4H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16PDE3BPDE3AAGTR1 | |
| SCHEMBL16486519 | 0.82 | BRD4 (0.71) | BRD4H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16PDE3BPDE3AAGTR1 | |
| SCHEMBL16486520 | 0.81 | BRD4 (0.68) | BRD4H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16PDE3BPDE3AAGTR1 | |
| SCHEMBL7315901 | 0.80 | BRD4 (0.67) | BRD4H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16PDE3BPDE3AAGTR1 | |
| SCHEMBL15723867 | 0.78 | BRD4 (1.00) | BRD4H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | |
| SCHEMBL16489431 | 0.77 | BRD4 (1.00) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296748-B2 | Pyridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-29 | — | — | US | disclosed |
| US-20150246919-A1 | PYRIDINONES | BOEHRINGER INGELHEIM INT (DE) | 2015-09-03 | — | — | US | disclosed |
| US-20150051208-A1 | PYRIDINONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-19 | — | — | US | disclosed |
| WO-2015022332-A1 | PYRIDINONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051208-A1 | PYRIDINONES | MKI67, XDH, CDK6 | BRD4 1346/4885H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 537/4885PDE3B 689/4885 |
| US-20150246919-A1 | PYRIDINONES | MKI67, XDH, CDK6 | BRD4 1346/4885H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 537/4885PDE3B 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.